Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response

Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response

Immune checkpoint inhibitors provide clinical benefit to a subset of patients with metastatic NSCLC, yet the reliable prediction of long-term outcomes remains challenging. We conducted a prospective phase 2 clinical trial to evaluate circulating tumor DNA (ctDNA) as a surrogate biomarker for early c...

Full description

Saved in:
Bibliographic Details
Main Authors: Iris van 't Erve, PhD, Isabelle Blanchard, BS, Judy Y. Pagtama, MSN, Alison J. Holmes Tisch, MSN, Ash A. Alizadeh, MD, PhD, Kavitha Ramchandran, MD, Heather A. Wakelee, MD, Sukhmani K. Padda, MD, Maximilian Diehn, MD, PhD, Joel W. Neal, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:JTO Clinical and Research Reports
Subjects:
NSCLC
Lung cancer
Biomarkers
Liquid biopsies
ctDNA
Translational research
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000943
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364325000943

Similar Items